Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts

Blood

Volumn 91, Issue 7, 1998, Pages 2482-2490

  Arguello, Francisco ^b   Alexander, Mark ^b   Sterry, Judith A ^b   Tudor, Gabriela ^b   Smith, Erik M ^b   Kalavar, Naina T ^b   Greene Jr , John F ^b   Koss, William ^b   Morgan, C David ^b   Stinson, Sherman F ^b   Siford, Timothy J ^b   Alvord, W Gregory ^b   Klabansky, Richard L ^b   Sausville, Edward A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLAVOPIRIDOL;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; FEMALE; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA; LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; FLAVONOIDS; GROWTH INHIBITORS; HL-60 CELLS; HUMANS; IMMUNOSUPPRESSION; LEUKEMIA; LYMPHOCYTES; LYMPHOMA; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PIPERIDINES;

EID: 0032055497     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Czech J, Hoffmann D, Naik R, Sadlacek HH: Antitumoral activity of flavone L 86-8275. J Oncol 6:31, 1995
2. Kaur G, Stetler-Stevenson M, Sebers S, Worland P, Sedlacek H, Myers C, Czech J, Naik R, Sausville E: Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J Natl Cancer Inst 84:1736, 1992
3. Harmon AD, Weiss U, Silverton JV: The structure of rohitukine, the main alkaloid of Amoora rohituka (Syn. Aphanamixis polystachya) (Maliaceae). Tetrahedron Let 8:721, 1979
4. Naik RG, Kattige SL, Bhat SB, Alreja B, de Souza NJ, Rupp RH: An antiinflammatory cum immunomodulatory piperidinylbenzopyranone from Dysoxylum Binectariferum: Isolation, structure and total synthesis. Tetrahedron 44:2081, 1988
5. Sanyal M, Datta PC: Pharmacognosy of Aphanamixis polystachya stem bark. Q J Crude Drug Res 19:113, 1981
6. Jain A, Srivastava SK: 8-C-methyl-quercetin-3-O-β-D-xylopyranoside, a new flavone glycoside from roots of Amoora rohituka. J Nat Prod 48:299, 1985
7. Kundu CAB, Chakrabortty T, Chandrasekharan S: Extractives of Aphanamixix polystachya wall (Parker). Tetrahedron 26:1859, 1970
8. Desai D, Gu Y, Morgan DO: Activation of human cyclin-dependent kinases in vitro. Mol Biol Cell 3:571, 1992
9. Morgan DO: Principles of CDK regulation. Nature 374:131, 1995
10. cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Biochem Pharmacol 46:1831, 1993
11. Losiewicz MD, Carlson BA, Kaur G, Sausville EA, Worland PJ: Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. Biochem Biophys Res Comm 201:589, 1994
12. Carlson BA, Duba MM, Sausville EA, Brizuela L, Worland PJ: Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinases (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res 56:2973, 1996
13. Filgueira-De-Azevedo W, Muller-Dieckmann H-J, Schulze-Gahmen U, Worland PJ, Sausville EA, Kim S-H: Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc Natl Acad Sci USA 93:2735, 1996
14. Sedlacek HH, Czech J, Naik R, Kaur G, Worland P, Losiewicz M, Parker B, Carlson B, Smith A, Senderowicz A, Sausville E: Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy. Int J Oncol 9:1143, 1996
15. Drees M, Dengler WA, Roth T, Labonte H, Mayo J, Malspeis L, Grever M, Sausville EA, and Fiebig HH: Flavopiridol (L86-8275): Selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells. Clinical Cancer Res 3:273, 1997
16. Senderowicz AM, Headlee D, Stinson S, Lush RM, Figg WD, Pluda J, Sausville EA: A phase I trial of flavopiridol (FLA), a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. Proc ASCO 16:226, 1997 (abstr 793)
17. Parker BW, Kaur G, Nieves-Niera W, Taimi M, Kolhagen G, Shimizu T, Losiewicz MD, Pommier Y, Sausville EA, Senderowicz AM: Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood 91:458, 1998
18. Arguello F, Baggs RB, Harwell SE, Frantz CN, Cohen HJ. Effect of IL-1 alfa on experimental bone marrow metastasis. Int J Cancer 52:802, 1992
19. Arguello F, Sterry JA, Zhao YZ, Alexander MRA, Shoemaker RH, Cohen HJ: Two serologic markers to monitor the engraftment, growth and treatment response of human leukemias in severe combined immunodeficient mice. Blood 87:4325, 1996
20. v). Cancer Res 52:2304, 1992
21. Testi R, Phillips JH, Lannier LL: T cell activation via Leu-23 (CD69). J Immunol 143:1123, 1989
22. Morgan CD, Mills K, Lefkowitz DL, Lefkowitz SS: An improved colorimetric assay for tumor necrosis factor using WEHI 164 cell cultures on novel microtiter plates. J Immunol Methods 145:259, 1991
23. Distelhorst CK, Lam M, McCormick TS: Bcl-2 inhibits hydrogen peroxide-induced ER Ca2+ pool depletion. Oncogene 12:2051, 1996
24. Snover DC, Filipovich AH, Ramsay NK, Weisdorf SA, Kersey JH: Graft-versus-host-disease-like histopathologic findings in pre-bone-marrow transplantation biopsies of patients with severe T-cell deficiency. Transplantation 39:95, 1985
25. Lee EY, Clouse RE, Aliperti G, DeSchryver-Kacskemeti K: Small intestinal lesion resembling graft-vs-host disease: A case report in immunodeficiency and review of the literature. Arch Pathol Lab Med 115:529, 1991
26. Larocca LM, Piantelli M, Leone G, Sica S, Teofili L, Benedetti-Panici P, Scambia G, Mancuso S, Capelli A, Ranelletti FO: Type II oestrogen binding sites in acute lymphoid and myelod leukemias: Growth inhibitory effect of oestrogen and flavonoids. Br J Haematol 75:489, 1990
27. Larocca LM, Piantelli M, Leone G, Sica S, Teofili L, Benedetti-Panici P, Scambia G, Mancuso S, Capelli A, Ranelletti FO: Antiproliferative activity of quercetin on normal bone marrow and leukemic progenitors. Br J Haematol 79:562, 1991
28. Larocca LM, Teofili L, Sica S, Piantelli M, Maggiano N, Leone G, Ranelletti FO: Quercetin inhibits the growth of leukemic progenitors and induces the expression of transforming growth factor-β1 in these cells. Blood 85:3654, 1995
29. Post JFM, Varma RS: Growth inhibitory effects of bioflavonoids and related compounds on human leukemic CEM-C1 and CEM-C7 cells. Cancer Lett 67:207, 1992
30. Markaverich BM, Roberts RR, Alejandro MA, Johson GA, Middleditch BS, Clark JH: Bioflavonoid interaction with rat uterine type II binding sites and cell growth inhibition. J Steroid Biochem Mol Biol 30:1, 1988
31. Markaverich BM, Gregory RR: Preliminary assessment of luteolin as an affinity ligand for type II estrogen binding sites in rat uterine nuclear extracts. Steroids 58:268, 1993
32. Jaxel C, Taudou G, Portemer C, Mirambeau G, Panijel J, Duguet M: Topoisomerase inhibitors induce irreversible fragmentation of replicated DNA in concanavalin A stimulated splenocytes. Biochem 27:95, 1988
33. Onishi Y, Azuma Y, Sato Y, Mizuno Y, Tadakuma T, Kizaki H: Topoisomerase inhibitors induce apoptosis in thymocytes. Biochem Biophys Acta 1175:147, 1993
34. McCabe MJ, Orrenius S: Genistein induces apoptosis in immature human thymocytes by inhibiting topoisomerase-II. Biochem Biophys Res Commun 194:944, 1993
35. Bible KC, Kaufman SH: Flavopiridol: A cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res 56:4856, 1996
36. Perkins ND, Felzien LK, Betts JC, Leung K, Beach DH, Nabel GJ: Regulation of NF-kappaB by cyclin-dependent kinases associated with the p300 coactivator. Science 275:523, 1997
37. Hickman JA: Apoptosis induced by anticancer agents. Cancer Metastasis Rev 11:121, 1992
38. Meijer L: Chemical inhibitors of cyclin-dependent kinases. Trends Cell Biol 6:393, 1996